Trial Profile
AZA PH GL 2003 CL 001 - Extension A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2017
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 12 Jan 2017 New trial record